March 25, 2017 8:08 AM ET

Pharmaceuticals

Company Overview of Dr. Reddy's Laboratories Limited

Company Overview

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients (APIs) and intermediates, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services; and manufactures and sells APIs and steroids in acco...

8-2-337, Road No. 3

Banjara Hills

Hyderabad,  500034

India

Founded in 1984

22,175 Employees

Phone:

91 40 4900 2900

Fax:

91 40 4900 2999

Key Executives for Dr. Reddy's Laboratories Limited

Co-Chairman, Chief Executive Officer, Managing Director and Member of the Management Council
Age: 56
Total Annual Compensation: 8.3M
Chairman of the Board and Member of the Management Council
Age: 49
Total Annual Compensation: 6.3M
Compensation as of Fiscal Year 2016.

Dr. Reddy's Laboratories Limited Key Developments

Dr. Reddy's Laboratories Announces US District Court's Opinion Relating to Patent Infringement

Dr. Reddy's Laboratories Ltd. announced that, the United States District Court for the District of New Jersey issued its opinion regarding Helsinn Healthcare's patent infringement claims against Dr. Reddy's Laboratories' proposed palonosetron product, pursuant to a "paper" NDA under Section 505(b)(2) of the Food, Drug and Cosmetic Act. The court found that Dr. Reddy's proposed palonosetron hydrochloride 0.25 mg /5 ml product infringes certain claims of U.S. Patent Nos. 7,947,724, 8,729,094 and 9,066,980, and that the asserted claims of the '094 and '980 Patents were not invalid.

Dr. Reddy's Laboratories Limited Announces Unaudited Consolidated Cash Flow Earnings Results for the Nine Months Ended December 31, 2016

Dr. Reddy's Laboratories Limited announced unaudited consolidated cash flow earnings results for the nine months ended December 31, 2016. For the nine months, the company reported net cash from operating activities of INR 12,996 million against INR 31,991 million a year ago. Expenditure on property, plant and equipment was INR 9,325 million against INR 8,709 million a year ago. Expenditure on other intangible assets was INR 28,307 million against INR 2,606 million a year ago.

BioMarin Pharmaceutical Inc. Sues Dr. Reddy's Laboratories Ltd. to Stop Generic Version of its $90,000 Year Drug

BioMarin Pharmaceutical Inc. said that on February 6, 2017 in U.S. District Court in New Jersey that a version of the drug Kuvan by Dr. Reddy's Laboratories Ltd. infringes on six BioMarin patents. The Indian company late last year asked the Food and Drug Administration to approve its powder version of Kuvan, saying that BioMarin's patents are invalid, unenforceable or will not be infringed by manufacturing, use or sale. BioMarin's suit does not ask for a specific award amount, but the company asks for "monetary relief together with interest" as well as attorneys' fees, costs and expenses of the suit and any award the court would add. Suits between brand-name drug developers and generic drug makers are not unusual; in fact, there is a whole system of rules that both types of companies must follow. But the stakes are high for BioMarin, since Kuvan is a one-of-its-kind drug with an average price of $90,000 a year. Kuvan is dosed by the weight of the patient, and its typical users are children, so as patients get older and weigh more, the annual cost of the drug increases. Through the first three quarters of last year, Kuvan was BioMarin's second-best-selling drug with $258 million in revenue. That was 47% higher than the same period in 2015. Dr. Reddy's is the second generic drug maker to attempt to sell a powder version of Kuvan. Par Pharmaceutical Cos. Inc. that earlier had sought to market Kuvan tablets, was sued in February 2016 by BioMarin. That case is ongoing.

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
November 24, 2016
Imperial Credit Pvt. Ltd.
Merger/Acquisition
July 27, 2016
Teva Pharmaceutical Industries Limited, Rights and Assets Related to 79 Pharmaceutical Products
Merger/Acquisition
June 11, 2016
Portfolio of Eight Abbreviated New Drug Applications in the US
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Dr. Reddys Laboratories Limited, please visit www.drreddys.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.